Go Pro

Rapport Therapeutics (RAPP) Stock Forecast & Price Target

Rapport Therapeutics logo
$48.42 +1.00 (+2.11%)
As of 08/17/2026 04:00 PM Eastern

Rapport Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
0
Buy
12

Based on 13 Wall Street analysts who have issued ratings for Rapport Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 1 has given a sell rating, 10 have given a buy rating, and 2 have given a strong buy rating for RAPP.

Consensus Price Target

$62.86
29.82% Upside
According to the 13 analysts' twelve-month price targets for Rapport Therapeutics, the average price target is $62.86. The highest price target for RAPP is $80.00, while the lowest price target for RAPP is $46.00. The average price target represents a forecasted upside of 29.82% from the current price of $48.42.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RAPP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RAPP Analyst Ratings Over Time

TypeCurrent Forecast
8/18/25 to 8/18/26
1 Month Ago
7/19/25 to 7/19/26
3 Months Ago
5/20/25 to 5/20/26
1 Year Ago
8/18/24 to 8/18/25
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$62.86$57.86$56.83$29.50
Forecasted Upside29.82% Upside35.75% Upside59.11% Upside102.19% Upside
Consensus RatingBuyModerate BuyModerate BuyBuy

RAPP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RAPP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Rapport Therapeutics Stock vs. The Competition

TypeRapport TherapeuticsHealthcare CompaniesBroader Market
Consensus Rating Score
3.00
2.30
2.53
Consensus RatingBuyHoldModerate Buy
Predicted Upside29.82% Upside796.16% Upside12.15% Upside
News Sentiment Rating
Positive News

See Recent RAPP News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/17/2026
Tiago Fauth
Not Rated
Reiterated RatingStrong-Buy$75.00+58.16%
8/17/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 Reiterated RatingStrong-Buy
8/12/2026
HC Wainwright logo
HC Wainwright
4 of 5 stars
Douglas Tsao
5 of 5 stars
Boost TargetBuy$40.00 ➝ $66.00+37.99%
8/5/2026Reiterated RatingBuy$65.00+54.73%
7/28/2026 Initiated CoverageOutperform
7/17/2026 Reiterated RatingSell (D-)
6/24/2026Initiated CoverageOutperform$52.00+33.74%
6/2/2026 Reiterated RatingMarket Outperform
5/18/2026Initiated CoverageBuy$44.00 ➝ $56.00+59.18%
3/11/2026Boost TargetOverweight$43.00 ➝ $46.00+51.12%
Your 10X AI demo is starting… (Ad)

Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investment of 17 million dollars. He is known for predicting the 2020 market crash with striking accuracy. Today he is hosting a free live demo of his newest AI-driven trading approach, showing how he analyzes market data without guesswork or speculation.tc pixel

Register now to watch the free AI trading demo live
3/9/2026 Reiterated RatingBuy
12/19/2025 Reiterated RatingBuy
11/7/2025Boost TargetMarket Outperform$77.00 ➝ $80.00+218.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:15 AM ET.


RAPP Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Rapport Therapeutics is $62.86, with a high forecast of $80.00 and a low forecast of $46.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rapport Therapeutics in the last year. There is currently 1 sell rating, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPP shares.

According to analysts, Rapport Therapeutics's stock has a predicted upside of 29.82% based on their 12-month stock forecasts.

Rapport Therapeutics has been rated by research analysts at BTIG Research, Citigroup, HC Wainwright, Leerink Partners, Raymond James Financial, UBS Group, Weiss Ratings, and William Blair in the past 90 days.

Analysts like Rapport Therapeutics more than other "healthcare" companies. The consensus rating for Rapport Therapeutics is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how RAPP compares to other companies.


This page (NASDAQ:RAPP) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners